The potentially protective effect of dapagliflozin on the development of cardiotoxicity in cancer patients

Back

ESC Professional Premium Access

The potentially protective effect of dapagliflozin on the development of cardiotoxicity in cancer patients

Session: Cardiotoxicity: mechanisms, biomarkers, and treatment

Topic: Cardio-Oncology

Speaker: Doctor S. Maragkoudakis (Chania, GR)

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Doctor Spyridon Maragkoudakis

General Hospital St. George, Chania (Greece)

0 follower

7 more presentations in this session

SGLT2 i Dapagliflozin reduces NF-kB expression in heart and kydneys of preclinical models exposed to doxorubicin through MYd-88 and NLRP3 pathways: an hystological study

Speaker: Doctor N. Maurea (Naples, IT)

SGLT2i Dapagliflozin decreases NLRP3, IL-1 and PCSK9 expression in preclinical models of short-term doxorubicin cardiotoxicity

Speaker: Doctor N. Maurea (Naples, IT)

The use of high sensitivity troponin T as a biomarker of anthracycline cardiotoxicity

Speaker: Doctor C. Bannister (London, GB)

The utility of the HFA-ICOS cardiotoxicity risk assessment tool for HER2-targeted cancer therapies in patients with metastatic breast cancer: from theory to clinical practice.

Speaker: Doctor D. Leocachin Parra (Mexico City, MX)

Differences in the prevalence of cardiovascular toxicity in a cohort of female breast cancer patients according to the different cardiotoxicity definitions

Speaker: Doctor J. Herrera (Cordoba, ES)

Access the full session

Cardiotoxicity: mechanisms, biomarkers, and treatment

Speakers: Doctor S. Maragkoudakis, Doctor N. Maurea, Doctor N. Maurea, Doctor C. Bannister, Doctor D. Leocachin Parra...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources